Literature DB >> 8878617

In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

H M Wexler1, E Molitoris, D Molitoris, S M Finegold.   

Abstract

The antimicrobial activity of trovafloxacin for 557 strains of anaerobic bacteria was determined by the National Committee for Clinical Laboratory Standards-approved Wadsworth agar dilution technique. The species tested included Bacteroides fragilis (n = 91), other members of the B. fragilis group (n = 130), Campylobacter gracilis (n = 15), other Bacteroides spp. (n = 16), Prevotella spp. (n = 49), Porphyromonas spp. (n = 15), Fusobacterium spp. (n = 62), Bilophila wadsworthia (n = 24), Sutterella wadsworthensis (n = 21), Clostridium spp. (n = 61), Peptostreptococcus spp. (n = 38), and gram-positive non-spore-forming rods (n = 35). Trovafloxacin inhibited all strains of B. fragilis at < or = 0.5 microgram/ml, 99% of other B. fragilis group species at < or = 2 micrograms/ml, and 96% of all anaerobes tested at < or = 2 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878617      PMCID: PMC163509     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Comparative activity of ciprofloxacin against anaerobic bacteria.

Authors:  V L Sutter; Y Y Kwok; J Bulkacz
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

2.  Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.

Authors:  R A Venezia; D M Yocum; E M Robbiano; R M Echols
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

3.  The antibiotic sensitivity of the Bacteroides fragilis group in the United Kingdom.

Authors:  A R Fox; I Phillips
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

4.  In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria.

Authors:  P B Fernandes; N Shipkowitz; R R Bower; K P Jarvis; J Weisz; D T Chu
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

5.  Sutterella wadsworthensis gen. nov., sp. nov., bile-resistant microaerophilic Campylobacter gracilis-like clinical isolates.

Authors:  H M Wexler; D Reeves; P H Summanen; E Molitoris; M McTeague; J Duncan; K H Wilson; S M Finegold
Journal:  Int J Syst Bacteriol       Date:  1996-01

6.  The comparative in-vitro activity of eight newer quinolones and nalidixic acid.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

7.  Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections.

Authors:  B M Jones; I Geary; M E Lee; B I Duerden
Journal:  J Antimicrob Chemother       Date:  1986-06       Impact factor: 5.790

8.  Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.

Authors:  A M Clarke; S J Zemcov
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

9.  In vitro activities of three of the newer quinolones against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

10.  Is ciprofloxacin active against clinically important anaerobes?

Authors:  B Watt; F V Brown
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

View more
  20 in total

Review 1.  Quinolones: which generation for which microbe?

Authors:  M K Lee; M S Kanatani
Journal:  West J Med       Date:  1999-06

2.  Comparative antianaerobic activity of BMS 284756.

Authors:  D B Hoellman; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  R Schaumann; G Ackermann; B Pless; M C Claros; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children.

Authors:  E Könönen; A Kanervo; K Salminen; H Jousimies-Somer
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 6.  Trovafloxacin.

Authors:  M Haria; H M Lamb
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

7.  Antibiotic resistance in bacteria isolated from subgingival plaque in a norwegian population with refractory marginal periodontitis.

Authors:  Trude Handal; Dominique A Caugant; Ingar Olsen
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

8.  Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.

Authors:  Mihaela Peric; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.

Authors:  Kaori Tanaka; Hiroshige Mikamo; Ken'ichi Nakao; Kunitomo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

10.  Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents.

Authors:  J Mättö; S Asikainen; M L Väisänen; B Von Troil-Lindén; E Könönen; M Saarela; K Salminen; S M Finegold; H Jousimies-Somer
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.